Our study highlights the intricate interplay between insulin and IGF1 signaling in the hypothalamus and suggests that targeting IGF1 resistance may offer new therapeutic avenues for treating metabolic disorders associated with hyperinsulinemia. Here, INS is linked to metabolic disease.